<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214811</url>
  </required_header>
  <id_info>
    <org_study_id>MxB Ag 01</org_study_id>
    <nct_id>NCT01214811</nct_id>
  </id_info>
  <brief_title>Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing</brief_title>
  <official_title>Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the change in signs of inflammation/local infection
      when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers
      (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need* of
      topical antimicrobial treatment according to the physician.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigation is designed as an open, non-controlled, post-marketing clinical follow-up.
      Subjects with chronic ulcers or partial thickness burns (including donor sites) at 2 sites
      will be included. Each subject with a chronic ulcer will be seen once a week for a maximum of
      4 weeks or until desired treatment effect is obtained, whichever occurs earlier. Each subject
      with a partial thickness burn/donor site will be followed once a week for a maximum of 3
      weeks or until desired treatment effect is obtained, whichever occurs earlier. All dressing
      changes will be done according to clinical routine practices and will follow IFU (instruction
      for use)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Are at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Area at Visit 2</measure>
    <time_frame>After one week</time_frame>
    <description>At each visit the wound length and width is measured and calculated in cm2.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Inflammation</condition>
  <condition>Burns</condition>
  <condition>Ulcers</condition>
  <arm_group>
    <arm_group_label>Mepilex Border Ag</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non comparative study with one active arm - Mepilex Border Ag</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepilex Border Ag</intervention_name>
    <description>Mepilex Border Ag may be left in place for up to seven days, depending on the condition.</description>
    <arm_group_label>Mepilex Border Ag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with a chronic ulcer (venous leg, diabetic foot and pressure ulcers) or a
             partial thickness burn where an antimicrobial action is indicated* as judged by the
             investigator

          -  Male or female, 18 years and above, both in- and out-patients

          -  Signed Informed Consent Form

        Exclusion Criteria:

          -  Wound size equal to or above 9.5x15cm for the wound/burn to be included in the
             investigation

          -  Subject not expected to follow the investigation procedures

          -  TBSA &gt; 10% (partial thickness burns only)

          -  HbA1C value &gt; 7.2. (To be measured if BMI &gt; 30)

          -  Pregnant and breastfeeding women

          -  Pressure ulcers deeper than stage 3

          -  Deep pressure ulcers in need of a filler

          -  Subjects with known sensitivity to silver or any other dressing materials

          -  Subjects receiving radiation treatment or examinations e.g. X-ray, ultrasound,
             diathermy or Magnetic Resonance Imaging

          -  Subjects using oxidising agents such as hypochlorite solutions or hydrogen peroxide

          -  Subjects previously included in this investigation

          -  Subjects included in other ongoing clinical investigation at present or during the
             past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Latenser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UI burn Treatment Center,200 Hawkings Dr 8JCP Iowa City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for advanced wound care</name>
      <address>
        <city>Momtgomery</city>
        <state>Alabama</state>
        <zip>36111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burn treatment center</name>
      <address>
        <city>Iowa city</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Curative &amp; Palliative Care, Calvary Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <results_first_submitted>January 22, 2013</results_first_submitted>
  <results_first_submitted_qc>January 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2013</results_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>The change in signs of inflammation/local infection</keyword>
  <keyword>To evaluate the comfort, conformability,</keyword>
  <keyword>Pain during wear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Burns</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mepilex Border Ag</title>
          <description>Non comparative study with one active arm - Mepilex Border Ag
Mepilex Border Ag : Mepilex Border Ag may be left in place for up to seven days, depending on the condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mepilex Border Ag</title>
          <description>Non comparative study with one active arm - Mepilex Border Ag
Mepilex Border Ag : Mepilex Border Ag may be left in place for up to seven days, depending on the condition.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Are at Baseline</title>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wound Area at Visit 2</title>
        <description>At each visit the wound length and width is measured and calculated in cm2.</description>
        <time_frame>After one week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Border Ag</title>
            <description>Non comparative study with one active arm - Mepilex Border Ag
Mepilex Border Ag : Mepilex Border Ag may be left in place for up to seven days, depending on the condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Area at Visit 2</title>
          <description>At each visit the wound length and width is measured and calculated in cm2.</description>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mepilex Border Ag</title>
          <description>Non comparative study with one active arm - Mepilex Border Ag
Mepilex Border Ag : Mepilex Border Ag may be left in place for up to seven days, depending on the condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Viktoria Ahlenius KÃ¶rner</name_or_title>
      <organization>Molnlycke Health Care</organization>
      <phone>0046 31 7223000</phone>
      <email>viktoria.ahleniuskorner@molnlycke.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

